BTO-1 is a compound known as a Polo-like kinase (Plk) inhibitor, commonly employed for its effectiveness in regulating processes involving phosphorylation and dephosphorylation.

BTO-1 treatment induces prominent alterations in cellular processes across various cell lines. At a concentration of 50 μM for 4 hours in U20S cells, it leads to the formation of monopolar spindles in a significant portion of mitotic cells. In PTK cells, BTO-1 demonstrates a dose-dependent decrease in phospho-Cdc25C signaling when applied at 20 μM for 1 hour, and a roughly 20% reduction in H3 phosphorylation at a 25 μM dosage for the same duration, compared to control cells. Moreover, BTO-1 disrupts the recruitment of Rho and Rho-GEF in HeLa cells, crucial components for assembling functional contractile rings, highlighting its diverse impacts on cellular mechanisms[1][2].